Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)
Real-Time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors With Actionable Mutations
Sponsor: University of Virginia
A NA clinical study on ALK Gene Mutation and BRAF, this trial is ongoing. The trial is conducted by University of Virginia and has accumulated 10 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting NA
-
Jun 2025 — Dec 2025 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Aug 2023 — Mar 2024 [monthly]
Recruiting NA
-
Mar 2023 — Aug 2023 [monthly]
Recruiting NA
-
Sep 2022 — Mar 2023 [monthly]
Recruiting NA
-
Jul 2022 — Sep 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .